These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 32942039

  • 1. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A, RITERM study group.
    Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A, Bruchfeld A.
    Nephron Clin Pract; 2014 Nov; 128(3-4):277-82. PubMed ID: 25401966
    [Abstract] [Full Text] [Related]

  • 3. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, Conti G, Buemi M, Santoro D.
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
    Lan L, Lin Y, Yu B, Wang Y, Pan H, Wang H, Lou X, Lang X, Zhang Q, Jin L, Yang Y, Xiao L, Chen J, Han F.
    Am J Nephrol; 2024 Nov; 55(1):25-36. PubMed ID: 37963441
    [Abstract] [Full Text] [Related]

  • 5. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
    C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E, Champion K, Kronbichler A, Lightstone L, Jayne D, Wilson E, Griffith M.
    BMC Nephrol; 2024 Aug 07; 25(1):253. PubMed ID: 39112932
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.
    Kronbichler A, König P, Busch M, Wolf G, Mayer G, Rudnicki M.
    Wien Klin Wochenschr; 2013 Jun 07; 125(11-12):328-33. PubMed ID: 23624956
    [Abstract] [Full Text] [Related]

  • 7. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
    Peters HP, van de Kar NC, Wetzels JF.
    Neth J Med; 2008 Nov 07; 66(10):408-15. PubMed ID: 19011266
    [Abstract] [Full Text] [Related]

  • 8. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 9. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, Bruchfeld A, Mayer G, Rudnicki M.
    Am J Nephrol; 2014 Apr 15; 39(4):322-30. PubMed ID: 24751753
    [Abstract] [Full Text] [Related]

  • 10. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y, Moriyama T, Itabashi M, Takei T, Nitta K.
    Contrib Nephrol; 2018 Apr 15; 195():12-19. PubMed ID: 29734146
    [Abstract] [Full Text] [Related]

  • 11. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
    Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y, Japan Nephrotic Syndrome Cohort Study investigators.
    J Nephrol; 2022 May 15; 35(4):1135-1144. PubMed ID: 35366214
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ.
    Clin Nephrol; 1995 Jun 15; 43(6):375-81. PubMed ID: 7554521
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T, Masuda T, Saito S, Kato N, Ishimoto T, Kato S, Kosugi T, Tsuboi N, Kitamura H, Tsuzuki T, Ito Y, Maruyama S.
    Clin Exp Nephrol; 2019 Feb 15; 23(2):207-214. PubMed ID: 30121802
    [Abstract] [Full Text] [Related]

  • 14. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A, Piecha G, Więcek A.
    Transplant Proc; 2016 Nov 15; 48(9):3092-3094. PubMed ID: 27932154
    [Abstract] [Full Text] [Related]

  • 15. Long-term Rituximab Therapy in Adult Patients with Idiopathic Nephrotic Syndrome.
    El-Reshaid K, Al-Bader S, Madda JP.
    Saudi J Kidney Dis Transpl; 2022 Nov 15; 33(4):509-515. PubMed ID: 37929543
    [Abstract] [Full Text] [Related]

  • 16. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L, Wang W, Wu Y, Xie J, Li X, Pan X, Zhang W, Xu J, Cai Y, Ren H, Chen N.
    Drug Des Devel Ther; 2021 Nov 15; 15():1945-1953. PubMed ID: 34007154
    [Abstract] [Full Text] [Related]

  • 17. [Minimal change disease and focal segmental glomerulosclerosis].
    Müller-Deile J, Schenk H, Schiffer M.
    Internist (Berl); 2019 May 15; 60(5):450-457. PubMed ID: 30887070
    [Abstract] [Full Text] [Related]

  • 18. B cell suppression in primary glomerular disease.
    Rood IM, Hofstra JM, Deegens JK, Wetzels JF.
    Adv Chronic Kidney Dis; 2014 Mar 15; 21(2):166-81. PubMed ID: 24602466
    [Abstract] [Full Text] [Related]

  • 19. Rituximab in maintaining remission in adults with podocytopathy.
    Ramachandran R, Bharati J, Nada R, Minz R, Kohli HS.
    Nephrology (Carlton); 2020 Aug 15; 25(8):616-624. PubMed ID: 32297386
    [Abstract] [Full Text] [Related]

  • 20. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X, Fang L, Sheng L, Zhou X, Bai S, Zang X, Wang Y, Li M, Lv Z, Zhong Q, Yang X, Wang Y, Hu Y, Yan D, Shi Y, Chen H, Li J, Tao M, Zhuang S, Wang Y, Liu N.
    Ren Fail; 2023 Dec 15; 45(1):2237124. PubMed ID: 37482915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.